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1. INTRODUCTION {#cas13722-sec-0001}
===============

Renal cell carcinoma (RCC) is the most common form of adult kidney cancer. It accounts for approximately 3.8% of all newly diagnosed malignancies, and more than 140 000 people die worldwide every year.[1](#cas13722-bib-0001){ref-type="ref"} Approximately 80% of RCC patients are classified with clear cell RCC.[2](#cas13722-bib-0002){ref-type="ref"} Approximately 20%‐30% of patients are found with advanced RCC at diagnosis, and the frequency of 5‐year survival is only 12.1%. The treatment strategy of metastatic RCC remains confused.[3](#cas13722-bib-0003){ref-type="ref"} Recently developed molecularly targeted therapeutics and immunotherapies have improved the prognosis of patients with advanced RCC, but recurrence, progression of distant metastasis, and side‐effects remain important issues associated with these treatments.[4](#cas13722-bib-0004){ref-type="ref"} Searching for new therapeutic targets and developing useful prognostic markers are important issues to overcome in new treatments for RCC.

MicroRNAs (miRNAs), which are short, single‐strand RNAs (19‐22 nucleotides) belong to a group of noncoding RNA molecules that act as pivotal agents responsible for fine‐tuning RNA expression in a sequence‐dependent manner.[5](#cas13722-bib-0005){ref-type="ref"} A vast number of studies have reported that miRNAs are closely involved in the physiological and pathological processes of disease.[6](#cas13722-bib-0006){ref-type="ref"} In cancer cells, abnormal expression of miRNAs can disrupt regulatory networks and lead to cancer cell development, progression, metastasis, and drug resistance.[5](#cas13722-bib-0005){ref-type="ref"}, [7](#cas13722-bib-0007){ref-type="ref"}, [8](#cas13722-bib-0008){ref-type="ref"} We have identified antitumor miRNAs *(miR‐10a‐5p*,*miR‐29s*,*miR‐101*,*miR‐149*, and *miR‐451a)* and their targets that are involved in the pathogenesis of RCC.[9](#cas13722-bib-0009){ref-type="ref"}, [10](#cas13722-bib-0010){ref-type="ref"}, [11](#cas13722-bib-0011){ref-type="ref"}, [12](#cas13722-bib-0012){ref-type="ref"}, [13](#cas13722-bib-0013){ref-type="ref"} This strategy is a novel approach to identify new molecular targets and prognostic markers for RCC.

Previous miRNA biogenesis posits that the passenger strand of miRNA is degraded and does not regulate gene expression. Contrary to this concept, our miRNA expression signature of RCC showed that some miRNA passenger strands are aberrantly expressed in cancer tissues, for example, *miR‐139‐3p*,*miR‐144‐5p*,*miR‐145‐3p*, and *miR‐150‐3p*.[14](#cas13722-bib-0014){ref-type="ref"}, [15](#cas13722-bib-0015){ref-type="ref"}, [16](#cas13722-bib-0016){ref-type="ref"}, [17](#cas13722-bib-0017){ref-type="ref"} In fact, we found that some passenger strands actually act as antitumor miRNAs (*miR‐144‐5p*,*miR‐145‐3p*,*miR‐149‐3p*,*miR‐150‐3p*, and *miR‐199a‐3p*) through their targeting of oncogenes in several cancers.[12](#cas13722-bib-0012){ref-type="ref"}, [15](#cas13722-bib-0015){ref-type="ref"}, [16](#cas13722-bib-0016){ref-type="ref"}, [17](#cas13722-bib-0017){ref-type="ref"}, [18](#cas13722-bib-0018){ref-type="ref"}, [19](#cas13722-bib-0019){ref-type="ref"} These studies suggested the importance of analyzing passenger strands of miRNA duplex in cancer cells.

Our recent study showed that *miR‐451a* was significantly downregulated in RCC tissues and acted as an antitumor miRNA in RCC cells.[13](#cas13722-bib-0013){ref-type="ref"} Interestingly, *miR‐451a‐*regulated oncogenic targets were significantly associated with RCC pathogenesis.[13](#cas13722-bib-0013){ref-type="ref"} In the human genome, *miR‐451a*,*miR‐144‐5p* (the passenger strand), and *miR‐144‐3p* (the guide strand) are clustered together in chromosomal region 17q11.2. The Cancer Genome Atlas (TCGA) database analyses showed that low expression of *miR‐144‐5p* and *miR‐144‐3p* was significantly associated with poor prognosis of RCC patients (*P* = .00128 and *P* = 9.45 × 10^−5^ ~,~ respectively).

In this study, we focused on *miR‐144‐5p* because the functional significance of miRNA passenger strands in RCC pathogenesis is obscure. Here, we studied the antitumor roles of *miR‐144‐5p* and identified the oncogenic targets involved in the pathogenesis of RCC. We suggest that identification of novel functions of miRNA passenger strands and the RNA networks they regulate might enhance our understanding of the molecular pathogenesis of RCC.

2. MATERIALS AND METHODS {#cas13722-sec-0002}
========================

2.1. Clinical RCC specimens and cell lines {#cas13722-sec-0003}
------------------------------------------

We obtained a total of 18 clinical tissue specimens from RCC patients who underwent total nephrectomy at Chiba University Hospital (Chiba, Japan) between 2008 and 2015 (Table [1](#cas13722-tbl-0001){ref-type="table"}). All patients in our study provided signed informed consent, and the study protocol was approved by the Institutional Review Board of Chiba University (approval no. 484). We used 2 cell lines, 786‐O and A498, obtained from ATCC (Manassas, VA, USA).

###### 

Clinical features of 18 patients with clear cell renal cell carcinoma

  No.   Age, years   Gender   Grade            pT    INF   v   ly   eg or ig   fc   im   rc   rp   s   Remarks
  ----- ------------ -------- ---------------- ----- ----- --- ---- ---------- ---- ---- ---- ---- --- ---------
  1     71           F        G2               T1a   a     0   0    eg         1    0    0    0    0   qRT‐PCR
  2     74           M        G1 \> G2         T1a   a     0   0    eg         1    0    0    0    0   qRT‐PCR
  3     59           M        G3 \> G2         T1b   a     0   0    eg         1    0    0    0    0   qRT‐PCR
  4     52           M        G2 \> G3 \> G1   T1a   a     0   0    eg         1    0    0    0    0   qRT‐PCR
  5     64           M        G2 \> G3         T1b   a     0   0    eg         1    1    0    0    0   qRT‐PCR
  6     67           M        G2 \> G3 \> G1   T3a   b     1   0    ig         0    1    1    0    0   qRT‐PCR
  7     67           M        G2 \> G3 \> G1   T3a   b     1   0    ig         1    0    0    0    0   qRT‐PCR
  8     59           M        G3 \> G2         T3a   b     1   0    ig         0    0    0    0    0   qRT‐PCR
  9     73           M        G1 \> G3         T2a   a     0   1    eg         1    0    0    0    0   qRT‐PCR
  10    77           M        G1 \> G2         T1b   a     0   0    eg         1    0    0    0    0   qRT‐PCR
  11    77           M        G2 \> G1         T3a   a     1   0    eg         1    0    0    0    0   qRT‐PCR
  12    51           M        G2 \> G1         T1b   a     0   0    eg         0    0    0    0    0   qRT‐PCR
  13    78           M        G2 \> G1 \> G3   T1b   b     0   0    eg         1    0    0    0    0   qRT‐PCR
  14    57           M        G1 \> G2         T1a   a     0   0    eg         1    0    0    0    0   qRT‐PCR
  15    54           M        G2 \> G1         T3a   a     0   0    eg         0    0    1    0    0   qRT‐PCR
  16    54           M        G1 \> \>G3       T2b   a     0   0    eg         1    0    0    0    0   qRT‐PCR
  17    74           F        G1 \> G2         T2a   b     0   0    ig         1    0    0    0    0   qRT‐PCR
  18    65           M        G1 \> G2         T1b   b     0   0    ig         1    0    0    0    0   IHC

a, clearly bounded with noncancer surrounding tissue; b, intermediate type; eg, expansive growth; F, female; fc, capsular formation; ig, infiltrative growth; IHC, immunohistochemistry; im, intrarenal metastasis; INF, infiltration; ly, lymph node; M, male; qRT‐PCR, quantitative RT‐PCR; rc, renal capsule invasion; rp, pelvis invasion; s, sinus invasion; v, vein.

John Wiley & Sons, Ltd

2.2. Transfection of mature miRNA and siRNA into RCC cells {#cas13722-sec-0004}
----------------------------------------------------------

The following RNA species were used in this study: mature miRNAs, pre‐miR miRNA precursors (*hsa‐miR*‐*144‐5p*, assay ID: PM12631; *hsa‐miR*‐*144‐3p*, assay ID: PM11051; Applied Biosystems, Foster City, CA, USA), negative control miRNA (assay ID: AM 17111; Applied Biosystems), and siRNA (Stealth Select RNAi siRNA; si*‐SDC3*, P/N: HSS145253 and HSS145254; Invitrogen, Carlsbad, CA, USA). The transfection methods were described previously.[11](#cas13722-bib-0011){ref-type="ref"}, [20](#cas13722-bib-0020){ref-type="ref"}

2.3. Quantitative RT‐PCR {#cas13722-sec-0005}
------------------------

The procedures for PCR quantification were described previously.[11](#cas13722-bib-0011){ref-type="ref"}, [20](#cas13722-bib-0020){ref-type="ref"} TaqMan probes and primers for *SDC3* (P/N:Hs01568665_m1; Applied Biosystems) were assay‐on‐demand gene expression products. Quantitative RT‐PCRs (qRT‐PCRs) for *miR‐144‐5p* (P/N:002148; Applied Biosystems) and *miR‐144‐3p* (P/N:002676) were used to identify the expression levels of miRNAs according to the manufacturer\'s protocol. To normalize the data for quantification of mRNA and miRNAs, we used human *GAPDH* (P/N: Hs02786624_g1; Applied Biosystems), *GUSB* (P/N: Hs99999908_m1; Applied Biosystems), and *RNU48* (assay ID: 001006; Applied Biosystems).

2.4. Cell proliferation, migration, and invasion assays {#cas13722-sec-0006}
-------------------------------------------------------

Cell proliferation abilities were determined by XTT assays using Cell Proliferation Kit II (Sigma‐Aldrich, St. Louis, MO, USA). Cell migration was characterized with wound healing assays. Cell invasion abilities were determined with modified Boyden chambers containing Transwell‐precoated Matrigel membrane filter inserts.[11](#cas13722-bib-0011){ref-type="ref"}, [20](#cas13722-bib-0020){ref-type="ref"}

2.5. Incorporation of miR‐144‐5p or miR‐144‐3p into the RNA‐induced silencing complex by Ago2 immunoprecipitation {#cas13722-sec-0007}
-----------------------------------------------------------------------------------------------------------------

786‐O cells were transfected with 10 nmol/L miRNAs by reverse transfection. After 48 hours, immunoprecipitation was carried out using a human AGO2 miRNA isolation kit (Wako, Osaka, Japan).[16](#cas13722-bib-0016){ref-type="ref"} Expression levels of *miR‐144‐5p* or *miR‐144‐3p* were evaluated by qRT‐PCR. MicroRNA data were normalized to the expression of *miR‐26a* (P/N:000405; Applied Biosystems), which was not influenced by *miR‐144‐5p* or *miR‐144‐3p* transfection.

2.6. Western blot analysis {#cas13722-sec-0008}
--------------------------

Immunoblotting was carried out with monoclonal anti‐SDC3 antibodies (1:400 dilution; SAB4301620; Sigma‐Aldrich). We used anti‐GAPDH antibodies (1:10 000 dilution; ab8245; Abcam, Cambridge, UK) as an internal control.[11](#cas13722-bib-0011){ref-type="ref"}, [20](#cas13722-bib-0020){ref-type="ref"}

2.7. Identification of candidate genes regulated by *miR‐144‐5p* and *miR‐144‐3p* in RCC cells {#cas13722-sec-0009}
----------------------------------------------------------------------------------------------

Candidate genes regulated by *miR‐144‐5p* and *miR‐144‐3p* were identified by a combination of in silico and genomewide gene expression analyses. Genes possessing sequences regulated by *miR‐144‐5p* and *miR‐144‐3p* were obtained from the TargetScan database (<http://www.targetscan.org/vert_71/>). Upregulated genes in RCC were identified from publicly available datasets in the Gene Expression Omnibus (GEO; accession no. [GSE36895](GSE36895)) and we narrowed down the candidate genes as explained below. Oligo microarrays (Human GE 60K; Agilent Technologies, Santa Clara, CA, USA) were used for gene expression analyses. The microarray data were deposited into GEO (<http://www.ncbi.nlm.nih.gov/geo/>), with accession number [GSE106791](GSE106791). The Genomics Analysis and Visualization Platform was used for visualization of gene expression heat maps and clustering.[21](#cas13722-bib-0021){ref-type="ref"} The normalized mRNA expression values in the RNA sequencing data were processed and provided as Z scores. In the present study, patients were divided into two groups: Z‐score ≥ 0 and Z‐score \< 0.

2.8. Plasmid construction and dual‐luciferase reporter assay {#cas13722-sec-0010}
------------------------------------------------------------

The partial wild‐type sequence of the *SDC3* 3′‐UTR was inserted between the *Sgf*I‐*Pme*I restriction sites in the 3′‐UTR of the h*Rluc* gene in the psiCHECK‐2 vector (C8021; Promega, Madison, WI, USA). We used sequences that were missing the *miR‐144‐5p* target sites (position 2166‐2172). The synthesized DNA was cloned into the psiCHECK‐2 vector.[11](#cas13722-bib-0011){ref-type="ref"}, [20](#cas13722-bib-0020){ref-type="ref"}

2.9. Immunohistochemistry {#cas13722-sec-0011}
-------------------------

Tissue sections were incubated overnight at 4°C with anti‐SDC3 antibodies diluted 1:50 (SAB4301620; Sigma‐Aldrich).[11](#cas13722-bib-0011){ref-type="ref"}, [20](#cas13722-bib-0020){ref-type="ref"}

2.10. Regulation of targets downstream of SDC3 in RCC {#cas13722-sec-0012}
-----------------------------------------------------

We further investigated pathways regulated by *SDC3* in RCC cells. We analyzed gene expression using si‐*SDC3*‐transfected 786‐O cells. Microarray data were used for expression profiling of si‐*SDC3* transfectants. The microarray data were deposited into GEO (accession no. [GSE113066](GSE113066)).

2.11. Clinical data analysis based on TCGA datasets {#cas13722-sec-0013}
---------------------------------------------------

To investigate the clinical significance of miRNAs and genes in RCC, we used the RNA sequence database in TCGA (<https://tcga-data.nci.nih.gov/tcga/>). The gene expression and clinical data were obtained from cBioPortal (<http://www.cbioportal.org/>, the provisional data downloaded on 1 December 2017).[22](#cas13722-bib-0022){ref-type="ref"}, [23](#cas13722-bib-0023){ref-type="ref"}, [24](#cas13722-bib-0024){ref-type="ref"}

2.12. Statistical analysis {#cas13722-sec-0014}
--------------------------

Relationships between 2 or 3 variables and numerical values were analyzed with Mann‐Whitney *U* tests or Bonferroni‐adjusted Mann‐Whitney *U*‐tests. Spearman\'s rank tests were used to analyze the correlations of the expressions. Expert StatView software (version 5.0; SAS Institute, Cary, NC, USA) was used for these analyses. Univariate and multivariate Cox proportional hazard regression models were used to determine prognostic factors with JMP Pro 13 (SAS Institute Inc., Cary, NC, USA).

3. RESULTS {#cas13722-sec-0015}
==========

3.1. Expression levels of *miR‐144‐5p* and *miR‐144‐3p* in RCC clinical specimens {#cas13722-sec-0016}
---------------------------------------------------------------------------------

As shown in Figure [1](#cas13722-fig-0001){ref-type="fig"}, the expression levels of *miR‐144‐5p* and *miR‐144‐3p* were significantly lower in cancer tissues compared with those in adjacent noncancerous tissues (*P* = .0325 and *P* = .0329, respectively; Figure [1](#cas13722-fig-0001){ref-type="fig"}A,B). Furthermore, Spearman\'s rank test showed a positive correlation between the expression levels of *miR‐144‐5p* and *miR‐144‐3p* in clinical specimens (*R* = 0.891, *P* \< .0001; Figure [1](#cas13722-fig-0001){ref-type="fig"}C).

![Expression levels, clinical significance, and functional roles of *miR‐144‐5p* and *miR‐144‐3p* in renal cell carcinoma (RCC). A‐C, Expression levels of *miR‐144‐5p* and *miR‐144‐3p* in RCC clinical specimens. *RNU48* was used as an internal control. Spearman\'s rank test showed a positive correlation between the expression levels of *miR‐144‐5p* and *miR‐144‐3p*. D,E, From The Cancer Genome Atlas database, patients with low expression levels of either *miR‐144‐5p* or *miR‐144‐3p* had significantly reduced overall survival. F‐H, Cell proliferation was determined by XTT assays. Cell migration activity was determined using migration assays. Cell invasion activity was determined using Matrigel invasion assays. \**P* \< .005; \*\**P* \< .0001](CAS-109-2919-g001){#cas13722-fig-0001}

3.2. Clinical significance and functional roles of miR‐144‐5p and miR‐144‐3p in RCC {#cas13722-sec-0017}
-----------------------------------------------------------------------------------

From TCGA database, patients with low expression levels of both *miR‐144‐5p* and *miR‐144‐3p* were significantly associated with poor prognosis (*P* = .00128 and *P* = 9.45 × 10^−5^, respectively; Figure [1](#cas13722-fig-0001){ref-type="fig"}D,E).

We undertook gain‐of‐function assays using miRNA transfection into two RCC cell lines. Ectopic expression of *miR‐144‐5p* and *miR‐144‐3p* showed that both *miR‐144‐5p* and *miR‐144‐3p* reduced cancer cell proliferation, migration, and invasive abilities in comparison with mock and miR‐control transfectants (Figure [1](#cas13722-fig-0001){ref-type="fig"}F‐H).

3.3. Incorporation of miR‐144‐5p into the RNA‐induced silencing complex in RCC cells {#cas13722-sec-0018}
------------------------------------------------------------------------------------

We carried out immunoprecipitation with antibodies targeting Ago2, which plays a pivotal role in the RNA‐induced silencing complex (RISC). After transfection with *miR‐144‐5p* and immunoprecipitation by anti‐Ago2 antibodies, *miR‐144‐5p* levels were significantly higher than those of mock‐ or miR‐control‐transfected cells or those of *miR‐144‐3p*‐transfected 786‐O cells (*P* \< .0001; Figure [S1](#cas13722-sup-0001){ref-type="supplementary-material"}A). Similarly, after *miR‐144‐3p* transfection, *miR‐144‐3p* was detected by Ago2 immunoprecipitation (*P* \< .0001; Figure [S1](#cas13722-sup-0001){ref-type="supplementary-material"}B).

3.4. Identification of candidate targets of *miR‐144‐5p* and *miR‐144‐3p* regulation in RCC cells {#cas13722-sec-0019}
-------------------------------------------------------------------------------------------------

We searched for candidate targets using a combination of genomewide gene expression and in silico database analyses. The strategy for identification of *miR‐144‐5p* and *miR‐144‐3p* target genes is shown in Figure [S2](#cas13722-sup-0002){ref-type="supplementary-material"}. First, we identified 2078 and 1043 genes that had putative target sites for *miR‐144‐5p* and *miR‐144‐3p*, respectively in their 3′‐UTRs based upon the TargetScanHuman 7.1 database. Next, we narrowed down those presumptive targets to 227 and 268 genes, respectively based on expression levels that were upregulated (fold change \>1.5) in RCC tissues using the GEO database. Next, we identified 65 and 34 genes that were downregulated after *miR‐144‐5p* and *miR‐144‐3p* transfection, respectively into RCC cells (Log~2~ ratio \< −0.5; Tables [2](#cas13722-tbl-0002){ref-type="table"}, [3](#cas13722-tbl-0003){ref-type="table"}). In this study, we focused on *miR‐144‐5p*, the passenger strand of the *miR‐144* duplex. As shown in Figure [2](#cas13722-fig-0002){ref-type="fig"}, 65 candidate target genes of *miR‐144‐5p* were analyzed, allowing us to construct a heat map. Among those genes, 9 were significantly associated with poor prognosis in RCC patients (*P* \< .001; Figure [3](#cas13722-fig-0003){ref-type="fig"}). Heat map visualization of those genes is shown in Figure [4](#cas13722-fig-0004){ref-type="fig"}A. Patients with high gene signature expression (Z‐score ≥ 0) had poorer outcomes (disease‐free survival and overall survival) than those with low gene signature expression (Z‐score \< 0) (*P* \< .0001; Figure [4](#cas13722-fig-0004){ref-type="fig"}B,C). In the present study, we focused on syndecan‐3 (*SDC3*), reportedly related to carcinogenesis in several types of cancers.

###### 

*miR‐144‐5p* candidate target genes in renal cell carcinoma

  Entrez gene ID   Gene symbol   Gene name                                                                                                                                     Site count   GEO expression data fold change (tumor/normal)   A498 *miR‐144‐5p* transfection (Log~2~ ratio)   786‐O *miR‐144‐5p* transfection (Log~2~ ratio)   Average A498/786‐O *miR‐144‐5p* transfection (Log~2~ ratio)   Cytoband       TCGA data for OS (high vs low expression: *P*‐value)
  ---------------- ------------- --------------------------------------------------------------------------------------------------------------------------------------------- ------------ ------------------------------------------------ ----------------------------------------------- ------------------------------------------------ ------------------------------------------------------------- -------------- ------------------------------------------------------
  54478            *FAM64A*      Family with sequence similarity 64, member A                                                                                                  1            2.400                                            −1.290                                          −0.933                                           −1.111                                                        hs\|17p13.2    1.79E‐07
  2147             *F2*          Coagulation factor II (thrombin)                                                                                                              1            2.673                                            −0.234                                          −0.925                                           −0.579                                                        hs\|11p11.2    3.68E‐07
  9319             *TRIP13*      Thyroid hormone receptor interactor 13                                                                                                        1            2.551                                            −1.164                                          −0.652                                           −0.908                                                        hs\|5p15.33    9.70E‐07
  375248           *ANKRD36*     Ankyrin repeat domain 36                                                                                                                      1            1.775                                            −0.874                                          −0.841                                           −0.857                                                        hs\|2q11.2     4.23E‐05
  1063             *CENPF*       Centromere protein F, 350/400 kDa                                                                                                             1            2.699                                            −0.717                                          −0.360                                           −0.539                                                        hs\|1q41       7.01E‐05
  64151            *NCAPG*       Non‐SMC condensin I complex, subunit G                                                                                                        1            2.746                                            −1.624                                          −0.840                                           −1.232                                                        hs\|4p15.31    7.27E‐05
  29121            *CLEC2D*      C‐type lectin domain family 2, member D                                                                                                       1            2.558                                            −1.014                                          −1.455                                           −1.235                                                        hs\|12p13.31   9.14E‐05
  9672             *SDC3*        Syndecan 3                                                                                                                                    1            2.432                                            −0.894                                          −0.977                                           −0.936                                                        hs\|1p35.2     0.000271
  10509            *SEMA4B*      Sema domain, immunoglobulin domain (Ig), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 4B                              1            2.298                                            −0.692                                          −0.934                                           −0.813                                                        hs\|15q26.1    0.000821
  81552            *VOPP1*       Vesicular, overexpressed in cancer, prosurvival protein 1                                                                                     1            1.842                                            −0.406                                          −1.035                                           −0.720                                                        hs\|7p11.2     0.004190
  727936           *GXYLT2*      Glucoside xylosyltransferase 2                                                                                                                3            2.640                                            −0.590                                          −0.814                                           −0.702                                                        hs\|3p13       0.004620
  3832             *KIF11*       Kinesin family member 11                                                                                                                      1            2.461                                            −1.241                                          −1.236                                           −1.238                                                        hs\|10q23.33   0.004640
  29028            *ATAD2*       ATPase family, AAA domain containing 2                                                                                                        1            2.606                                            −0.844                                          −0.507                                           −0.676                                                        hs\|8q24.13    0.006000
  3090             *HIC1*        Hypermethylated in cancer 1                                                                                                                   1            2.709                                            −0.994                                          −0.022                                           −0.508                                                        hs\|17p13.3    0.009480
  51060            *TXNDC12*     Thioredoxin domain containing 12 (endoplasmic reticulum)                                                                                      1            1.579                                            −0.564                                          −0.765                                           −0.665                                                        hs\|1p32.3     0.009760
  710              *SERPING1*    Serpin peptidase inhibitor, clade G (C1 inhibitor), member 1                                                                                  1            2.015                                            −0.558                                          −0.536                                           −0.547                                                        hs\|11q12.1    0.016900
  59345            *GNB4*        Guanine nucleotide‐binding protein (G protein), beta polypeptide 4                                                                            1            1.862                                            −0.881                                          −1.421                                           −1.151                                                        hs\|3q26.33    0.053200
  1356             *CP*          Ceruloplasmin (ferroxidase)                                                                                                                   1            15.420                                           −1.753                                          −1.380                                           −1.566                                                        hs\|3q24       0.070000
  5272             *SERPINB9*    Serpin peptidase inhibitor, clade B (ovalbumin), member 9                                                                                     1            1.797                                            −0.462                                          −1.730                                           −1.096                                                        hs\|6p25.2     0.078200
  5046             *PCSK6*       Proprotein convertase subtilisin/kexin type 6                                                                                                 1            7.374                                            −0.930                                          −1.827                                           −1.379                                                        hs\|15q26.3    0.080000
  586              *BCAT1*       Branched chain amino acid transaminase 1, cytosolic                                                                                           2            3.076                                            −0.850                                          −1.324                                           −1.087                                                        hs\|12p12.1    0.100000
  54437            *SEMA5B*      Sema domain, seven thrombospondin repeats (type 1 and type 1‐like), transmembrane domain (TM) and short cytoplasmic domain, (semaphorin) 5B   1            7.089                                            −0.706                                          −2.687                                           −1.696                                                        hs\|3q21.1     0.109000
  317              *APAF1*       Apoptotic peptidase activating factor 1                                                                                                       1            1.839                                            −0.973                                          −1.014                                           −0.994                                                        hs\|12q23.1    0.121000
  10718            *NRG3*        Neuregulin 3                                                                                                                                  1            1.977                                            −1.645                                          −0.389                                           −1.017                                                        hs\|10q23.1    0.213000
  51316            *PLAC8*       Placenta‐specific 8                                                                                                                           2            2.750                                            −0.630                                          −1.962                                           −1.296                                                        hs\|4q21.22    0.249000
  7436             *VLDLR*       Very low density lipoprotein receptor                                                                                                         1            2.186                                            −0.455                                          −0.817                                           −0.636                                                        hs\|9p24.2     0.254000
  1050             *CEBPA*       CCAAT/enhancer binding protein (C/EBP), alpha                                                                                                 1            1.531                                            −0.877                                          −0.648                                           −0.763                                                        hs\|19q13.11   0.320000
  64919            *BCL11B*      B‐cell CLL/lymphoma 11B (zinc finger protein)                                                                                                 1            2.484                                            −0.178                                          −1.121                                           −0.649                                                        hs\|14q32.2    0.340000
  56950            *SMYD2*       SET and MYND domain containing 2                                                                                                              1            1.657                                            −0.501                                          −0.762                                           −0.631                                                        hs\|1q41       0.343000
  11096            *ADAMTS5*     ADAM metallopeptidase with thrombospondin type 1 motif, 5                                                                                     2            1.523                                            −0.188                                          −0.946                                           −0.567                                                        hs\|21q21.3    0.394000
  1009             *CDH11*       Cadherin 11, type 2, OB‐cadherin (osteoblast)                                                                                                 1            1.848                                            −0.792                                          −1.789                                           −1.290                                                        hs\|16q21      0.426000
  149628           *PYHIN1*      Pyrin and HIN domain family, member 1                                                                                                         1            1.968                                            −1.154                                          −1.032                                           −1.093                                                        hs\|1q23.1     0.474000
  27010            *TPK1*        Thiamin pyrophosphokinase 1                                                                                                                   1            1.578                                            −0.810                                          −0.591                                           −0.701                                                        hs\|7q35       0.487000
  8357             *HIST1H3H*    Histone cluster 1, H3 h                                                                                                                       1            3.446                                            −0.690                                          −1.521                                           −1.105                                                        hs\|6p22.1     0.516000
  4082             *MARCKS*      Myristoylated alanine‐rich protein kinase C substrate                                                                                         2            2.769                                            −1.310                                          −2.252                                           −1.781                                                        hs\|6q21       0.528000
  23468            *CBX5*        Chromobo × homolog 5                                                                                                                          2            1.659                                            −1.157                                          −1.216                                           −1.187                                                        hs\|12q13.13   0.549000
  79627            *OGFRL1*      Opioid growth factor receptor‐like 1                                                                                                          2            2.107                                            −0.940                                          −0.167                                           −0.553                                                        hs\|6q13       0.587000
  571              *BACH1*       BTB and CNC homology 1, basic leucine zipper transcription factor 1                                                                           1            1.649                                            −0.197                                          −1.127                                           −0.662                                                        hs\|21q21.3    0.622000
  23102            *TBC1D2B*     TBC1 domain family, member 2B                                                                                                                 1            1.654                                            −0.974                                          −0.531                                           −0.752                                                        hs\|15q24.3    0.693000
  4481             *MSR1*        Macrophage scavenger receptor 1                                                                                                               1            2.887                                            −1.581                                          −1.135                                           −1.358                                                        hs\|8p22       0.705000
  493              *ATP2B4*      ATPase, Ca++ transporting, plasma membrane 4                                                                                                  1            2.282                                            −1.285                                          −0.928                                           −1.106                                                        hs\|1q32.1     0.723000
  56124            *PCDHB12*     Protocadherin beta 12                                                                                                                         1            2.095                                            −0.179                                          −0.844                                           −0.512                                                        hs\|5q31.3     0.765000
  3556             *IL1RAP*      Interleukin 1 receptor accessory protein                                                                                                      1            1.775                                            −0.170                                          −1.024                                           −0.597                                                        hs\|3q28       0.774000
  9201             *DCLK1*       Doublecortin‐like kinase 1                                                                                                                    1            3.633                                            −1.282                                          −0.906                                           −1.094                                                        hs\|13q13.3    0.804000
  488              *ATP2A2*      ATPase, Ca++ transporting, cardiac muscle, slow twitch 2                                                                                      1            1.522                                            −1.297                                          −0.891                                           −1.094                                                        hs\|12q24.11   0.816000
  9545             *RAB3D*       RAB3D, member RAS oncogene family                                                                                                             1            1.956                                            −1.106                                          −0.074                                           −0.590                                                        hs\|19p13.2    0.846000
  4330             *MN1*         Meningioma (disrupted in balanced translocation) 1                                                                                            1            1.682                                            −0.170                                          −0.855                                           −0.512                                                        hs\|22q12.1    0.846000
  23036            *ZNF292*      Zinc finger protein 292                                                                                                                       2            2.177                                            −0.792                                          −0.573                                           −0.683                                                        hs\|6q14.3     0.900000
  9770             *RASSF2*      Ras association (RalGDS/AF‐6) domain family member 2                                                                                          1            6.147                                            −1.030                                          −0.058                                           −0.544                                                        hs\|20p13      0.911000
  11120            *BTN2A1*      Butyrophilin, subfamily 2, member A1                                                                                                          1            1.520                                            −1.328                                          −0.533                                           −0.930                                                        hs\|6p22.2     0.912000
  11237            *RNF24*       Ring finger protein 24                                                                                                                        1            1.606                                            −0.831                                          −0.578                                           −0.704                                                        hs\|20p13      0.918000
  23023            *TMCC1*       Transmembrane and coiled‐coil domain family 1                                                                                                 1            4.679                                            −0.791                                          −0.349                                           −0.570                                                        hs\|3q22.1     0.945000
  636              *BICD1*       Bicaudal D homolog 1 (Drosophila)                                                                                                             1            2.423                                            −0.557                                          −0.590                                           −0.574                                                        hs\|12p11.21   0.955000
  6424             *SFRP4*       Secreted frizzled‐related protein 4                                                                                                           1            1.786                                            −1.625                                          −1.025                                           −1.325                                                        hs\|7p14.1     0.980000
  54769            *DIRAS2*      DIRAS family, GTP‐binding RAS‐like 2                                                                                                          3            6.202                                            −0.204                                          −2.678                                           −1.441                                                        hs\|9q22.2     0.001190[a](#cas13722-note-0003){ref-type="fn"}
  196              *AHR*         Aryl hydrocarbon receptor                                                                                                                     1            1.745                                            −0.816                                          −1.261                                           −1.039                                                        hs\|7p21.1     0.011700[a](#cas13722-note-0003){ref-type="fn"}
  283              *ANG*         Angiogenin, ribonuclease, RNase A family, 5                                                                                                   2            1.617                                            −0.554                                          −0.906                                           −0.730                                                        hs\|14q11.2    0.015300[a](#cas13722-note-0003){ref-type="fn"}
  8490             *RGS5*        Regulator of G protein signaling 5                                                                                                            1            4.721                                            −0.938                                          −0.705                                           −0.821                                                        hs\|1q23.3     0.031700[a](#cas13722-note-0003){ref-type="fn"}
  54941            *RNF125*      Ring finger protein 125, E3 ubiquitin protein ligase                                                                                          1            1.527                                            −0.789                                          −0.321                                           −0.555                                                        hs\|18q12.1    0.038200[a](#cas13722-note-0003){ref-type="fn"}
  80854            *SETD7*       SET domain containing (lysine methyltransferase) 7                                                                                            1            2.225                                            −0.662                                          −0.854                                           −0.758                                                        hs\|4q31.1     0.045900[a](#cas13722-note-0003){ref-type="fn"}
  81575            *APOLD1*      Apolipoprotein L domain containing 1                                                                                                          1            3.953                                            −1.531                                          −1.101                                           −1.316                                                        hs\|12p13.1    2.21E‐06[a](#cas13722-note-0003){ref-type="fn"}
  143872           *ARHGAP42*    Rho GTPase activating protein 42                                                                                                              1            2.075                                            −1.289                                          −1.614                                           −1.452                                                        hs\|11q22.1    4.85E‐05[a](#cas13722-note-0003){ref-type="fn"}
  642273           *FAM110C*     Family with sequence similarity 110, member C                                                                                                 1            2.149                                            −1.376                                          −0.041                                           −0.708                                                        hs\|2p25.3     5.9E‐06[a](#cas13722-note-0003){ref-type="fn"}
  375287           *RBM43*       RNA binding motif protein 43                                                                                                                  1            1.630                                            −0.377                                          −0.994                                           −0.685                                                        hs\|2q23.3     6.29E‐05[a](#cas13722-note-0003){ref-type="fn"}
  4601             *MXI1*        MAX interactor 1, dimerization protein                                                                                                        1            1.987                                            −1.649                                          −0.513                                           −1.081                                                        hs\|10q25.2    9.79E‐05[a](#cas13722-note-0003){ref-type="fn"}

Poor prognosis with low gene expression.

GEO, Gene Expression Omnibus; OS, overall survival; TCGA, The Cancer Genome Atlas.

John Wiley & Sons, Ltd

###### 

*miR‐144‐3p* candidate target genes in renal cell carcinoma

  Entrez gene ID   Gene symbol   Gene name                                                                                     Conserved site count   Poorly conserved site count   GEO expression data fold change (tumor/normal)   A498 *miR‐144‐3p* transfection (Log~2~ ratio)   786‐O *miR‐144‐3p* transfection (Log~2~ ratio)   Average A498/786‐O *miR‐144‐3p* transfection (Log~2~ ratio)   Cytoband       TCGA data for OS (high vs low expression: *P*‐value)
  ---------------- ------------- --------------------------------------------------------------------------------------------- ---------------------- ----------------------------- ------------------------------------------------ ----------------------------------------------- ------------------------------------------------ ------------------------------------------------------------- -------------- ------------------------------------------------------
  5373             *PMM2*        Phosphomannomutase 2                                                                          1                      0                             1.580                                            −1.617                                          −1.020                                           −1.319                                                        hs\|16p13.2    2.18E‐07
  55165            *CEP55*       Centrosomal protein 55 kDa                                                                    1                      1                             4.202                                            −1.743                                          −1.130                                           −1.437                                                        hs\|10q23.33   6.94E‐07
  79733            *E2F8*        E2F transcription factor 8                                                                    1                      0                             4.133                                            −0.537                                          −0.722                                           −0.630                                                        hs\|11p15.1    0.00145
  9134             *CCNE2*       Cyclin E2                                                                                     1                      0                             2.430                                            −0.591                                          −1.823                                           −1.207                                                        hs\|8q22.1     0.00664
  23657            *SLC7A11*     Solute carrier family 7 (anionic amino acid transporter light chain, xc‐ system), member 11   1                      5                             2.678                                            −0.418                                          −1.195                                           −0.806                                                        hs\|4q28.3     0.02340
  1462             *VCAN*        Versican                                                                                      1                      1                             5.753                                            −0.695                                          −0.883                                           −0.789                                                        hs\|5q14.3     0.04670
  2335             *FN1*         Fibronectin 1                                                                                 1                      1                             5.453                                            −1.470                                          −0.105                                           −0.787                                                        hs\|2q35       0.07790
  5738             *PTGFRN*      Prostaglandin F2 receptor inhibitor                                                           1                      0                             2.242                                            −0.565                                          −0.981                                           −0.773                                                        hs\|1p13.1     0.08260
  57561            *ARRDC3*      Arrestin domain containing 3                                                                  1                      2                             1.705                                            −0.381                                          −0.940                                           −0.660                                                        hs\|5q14.3     0.11100
  11116            *FGFR1OP*     FGFR1 oncogene partner                                                                        1                      1                             1.551                                            −0.499                                          −0.881                                           −0.690                                                        hs\|6q27       0.17000
  7436             *VLDLR*       Very low density lipoprotein receptor                                                         1                      2                             2.186                                            −0.455                                          −0.817                                           −0.636                                                        hs\|9p24.2     0.25400
  1050             *CEBPA*       CCAAT/enhancer binding protein (C/EBP), alpha                                                 1                      0                             1.531                                            −0.877                                          −0.648                                           −0.763                                                        hs\|19q13.11   0.32000
  4154             *MBNL1*       Muscleblind‐like splicing regulator 1                                                         3                      0                             1.743                                            −0.610                                          −0.947                                           −0.779                                                        hs\|3q25.2     0.32100
  64919            *BCL11B*      B‐cell CLL/lymphoma 11B (zinc finger protein)                                                 1                      0                             2.484                                            −0.178                                          −1.121                                           −0.649                                                        hs\|14q32.2    0.34000
  11096            *ADAMTS5*     ADAM metallopeptidase with thrombospondin type 1 motif, 5                                     1                      2                             1.523                                            −0.188                                          −0.946                                           −0.567                                                        hs\|21q21.3    0.39400
  1009             *CDH11*       Cadherin 11, type 2, OB‐cadherin (osteoblast)                                                 1                      0                             1.848                                            −0.792                                          −1.789                                           −1.290                                                        hs\|16q21      0.42600
  3796             *KIF2A*       Kinesin heavy chain member 2A                                                                 1                      2                             2.008                                            −0.922                                          −1.005                                           −0.963                                                        hs\|5q12.1     0.44500
  55205            *ZNF532*      Zinc finger protein 532                                                                       1                      0                             1.899                                            −0.790                                          −1.560                                           −1.175                                                        hs\|18q21.32   0.50400
  4082             *MARCKS*      Myristoylated alanine‐rich protein kinase C substrate                                         1                      1                             2.769                                            −1.310                                          −2.252                                           −1.781                                                        hs\|6q21       0.52800
  79627            *OGFRL1*      Opioid growth factor receptor‐like 1                                                          1                      2                             2.107                                            −0.940                                          −0.167                                           −0.553                                                        hs\|6q13       0.58700
  22795            *NID2*        Nidogen 2 (osteonidogen)                                                                      1                      0                             1.527                                            −0.935                                          −0.208                                           −0.571                                                        hs\|14q22.1    0.62800
  2200             *FBN1*        Fibrillin 1                                                                                   2                      0                             2.173                                            −0.605                                          −1.049                                           −0.827                                                        hs\|15q21.1    0.63000
  10957            *PNRC1*       Proline‐rich nuclear receptor coactivator 1                                                   1                      0                             1.724                                            −0.640                                          −0.875                                           −0.757                                                        hs\|6q15       0.72000
  79365            *BHLHE41*     Basic helix‐loop‐helix family, member e41                                                     1                      2                             9.461                                            −0.947                                          −0.568                                           −0.758                                                        hs\|12p12.1    0.89500
  23036            *ZNF292*      Zinc finger protein 292                                                                       1                      1                             2.177                                            −0.792                                          −0.573                                           −0.683                                                        hs\|6q14.3     0.90000
  23023            *TMCC1*       Transmembrane and coiled‐coil domain family 1                                                 1                      0                             4.679                                            −0.791                                          −0.349                                           −0.570                                                        hs\|3q22.1     0.94500
  4131             *MAP1B*       Microtubule‐associated protein 1B                                                             1                      0                             2.795                                            −0.448                                          −0.880                                           −0.664                                                        hs\|5q13.2     0.99300
  8445             *DYRK2*       Dual‐specificity tyrosine‐(Y)‐phosphorylation regulated kinase 2                              2                      0                             1.729                                            −0.494                                          −0.518                                           −0.506                                                        hs\|12q15      0.000356[a](#cas13722-note-0005){ref-type="fn"}
  1003             *CDH5*        Cadherin 5, type 2 (vascular endothelium)                                                     1                      0                             2.616                                            −0.439                                          −0.643                                           −0.541                                                        hs\|16q21      0.00935[a](#cas13722-note-0005){ref-type="fn"}
  23097            *CDK19*       Cyclin‐dependent kinase 19                                                                    1                      2                             2.174                                            −0.145                                          −0.891                                           −0.518                                                        hs\|6q21       0.01660[a](#cas13722-note-0005){ref-type="fn"}
  2908             *NR3C1*       Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)                     1                      0                             2.111                                            −0.667                                          −1.105                                           −0.886                                                        hs\|5q31.3     0.01780[a](#cas13722-note-0005){ref-type="fn"}
  54492            *NEURL1B*     Neuralized E3 ubiquitin protein ligase 1B                                                     1                      0                             2.907                                            −0.637                                          −0.810                                           −0.723                                                        hs\|5q35.1     0.03430[a](#cas13722-note-0005){ref-type="fn"}
  54941            *RNF125*      Ring finger protein 125, E3 ubiquitin protein ligase                                          1                      1                             1.527                                            −0.789                                          −0.321                                           −0.555                                                        hs\|18q12.1    0.03820[a](#cas13722-note-0005){ref-type="fn"}
  114800           *CCDC85A*     Coiled‐coil domain containing 85A                                                             1                      0                             2.334                                            −1.409                                          −0.189                                           −0.799                                                        hs\|2p16.1     3.69E‐05[a](#cas13722-note-0005){ref-type="fn"}

Poor prognosis with low gene expression.

GEO, Gene Expression Omnibus; OS, overall survival; TCGA, The Cancer Genome Atlas.

John Wiley & Sons, Ltd

![Heat map showing the expression of 65 genes targeted by *miR‐144‐5p*](CAS-109-2919-g002){#cas13722-fig-0002}

![The Cancer Genome Atlas database analysis of putative targets of *miR‐144‐5p* in renal cell carcinoma. Kaplan‐Meier plots of overall survival with log‐rank tests for 9 genes regulated by *miR‐144‐5p* with high and low gene expression from The Cancer Genome Atlas database](CAS-109-2919-g003){#cas13722-fig-0003}

![Heat map showing gene expression and Kaplan‐Meier analysis of 9 candidate genes in renal cell carcinoma. A, Heat map visualization of 9 candidate genes. B, Kaplan‐Meier analysis of disease‐free survival of patients with high gene signature expression and those with a low gene signature expression. C, Kaplan‐Meier analysis of overall survival of patients with high gene signature expression and those with a low gene signature expression](CAS-109-2919-g004){#cas13722-fig-0004}

3.5. Direct regulation of *SDC3* by *miR‐144‐5p* in RCC cells {#cas13722-sec-0020}
-------------------------------------------------------------

We asked whether the expression of the *SDC3* gene and SDC3 protein decreased in *miR‐144‐5p*‐transfected RCC cells. As shown in Figure [5](#cas13722-fig-0005){ref-type="fig"}A,B, both mRNA and protein levels were significantly decreased by *miR‐144‐5p* transfection compared with the mock, miR‐control, or *miR‐144‐3p* transfectants.

![Regulation of *SDC3* expression by *miR‐144‐5p* in renal cell carcinoma cells. A, Expression levels of *SDC3* mRNA 48 hours after transfection with 10 nmol/L *miR‐144‐5p* or *miR‐144‐3p* into cell lines. *GAPDH* was used as an internal control. \**P* \< .0001. B, Protein expression of syndecan‐3 (SDC3) 72 hours after transfection with *miR‐144‐5p* or *miR‐144‐3p*. GAPDH was used as a loading control. C, *miR‐144‐5p* binding sites in the 3′‐UTR of *SDC3* mRNA. D, Dual‐luciferase reporter assays using vectors encoding putative *miR‐144‐5p* target sites (positions 2166‐2172) in the *SDC3* 3′‐UTR for both wild‐type and deletion‐type. Normalized data were calculated as the ratio of *Renilla*/firefly luciferase activities. \**P* \< .005; \*\**P* \< .001; \*\*\**P* \< .05](CAS-109-2919-g005){#cas13722-fig-0005}

Next, luciferase reporter assays with a vector that included the 3′‐UTR of *SDC3* were undertaken to confirm that *miR‐144‐5p* directly regulated *SDC3* in a sequence‐dependent manner. The TargetScanHuman database predicted that there was a binding site for *miR‐144‐5p* in the 3′‐UTR of *SDC3* (position 2166‐2172; Figure [5](#cas13722-fig-0005){ref-type="fig"}C). Cotransfection with *miR‐144‐5p* and vectors significantly decreased luciferase activity in comparison with those in mock and miR‐control transfectants (Figure [5](#cas13722-fig-0005){ref-type="fig"}D).

3.6. Effects of silencing *SDC3* on cell proliferation, migration, and invasion in RCC cells {#cas13722-sec-0021}
--------------------------------------------------------------------------------------------

We confirmed that the expression levels of *SDC3* mRNA and SDC3 protein were decreased by si‐*SDC3* in RCC cells (Figure [6](#cas13722-fig-0006){ref-type="fig"}A,B). Furthermore, we investigated the effects of silencing *SDC3* on cell proliferation, migration, and invasion in RCC cells. Cancer aggressiveness was significantly inhibited in si‐*SDC3* transfectants in comparison with that in mock‐ or miR‐control‐transfected cell lines (Figure [6](#cas13722-fig-0006){ref-type="fig"}C‐E).

![Effects of silencing *SDC3* in renal cell carcinoma cell lines. A, *SDC3* mRNA expression 72 hours after transfection with 10 nmol/L si‐*SDC3*\_1 or si‐*SDC3*\_2 into renal cell carcinoma cell lines. *GAPDH* was used as an internal control. B, Syndecan‐3 (SDC3) protein expression 72 hours after transfection with si‐*SDC3*\_1 or si‐*SDC3*\_2. GAPDH was used as a loading control. C, Cell proliferation was determined with XTT assays 72 hours after transfection with 10 nmol/L si‐*SDC3*\_1 or si‐*SDC3*\_2. D, Cell migration activity was determined by migration assays. E, Cell invasion activity was determined using Matrigel invasion assays. \**P* \< .0001](CAS-109-2919-g006){#cas13722-fig-0006}

3.7. Expression of SDC3 in RCC clinical specimens {#cas13722-sec-0022}
-------------------------------------------------

We examined the mRNA expression levels of *SDC3* in 17 RCC clinical specimens using qRT‐PCR. The mRNA expression levels of *SDC3* were significantly upregulated in cancer tissues compared with those in adjacent noncancerous tissues (Figure [7](#cas13722-fig-0007){ref-type="fig"}A). Spearman\'s rank test revealed a negative correlation between the expression of *SDC3* and *miR‐144‐5p* (*P* = .0409, *R* = −0.356, Figure [7](#cas13722-fig-0007){ref-type="fig"}B). Next, we investigated the expression levels of SDC3 in RCC clinical specimens by immunostaining. It was found that SDC3 was strongly overexpressed in several cancer lesions compared with that in adjacent noncancerous lesions with the same staining intensity (Figure [7](#cas13722-fig-0007){ref-type="fig"}C).

![Expression of *SDC3* in clinical specimens of renal cell carcinoma. A, Expression levels of *SDC3* in RCC clinical specimens. *GUSB* was used as an internal control. B, Spearman\'s rank test showed the negative correlation between *SDC3* expression and *miR‐144‐5p*. C, Immunostaining showed that SDC3 was strongly expressed in cancer lesions (100× and 400× magnification field)](CAS-109-2919-g007){#cas13722-fig-0007}

3.8. Downstream genes affected by silencing of *SDC3* in RCC cells {#cas13722-sec-0023}
------------------------------------------------------------------

Finally, we undertook a genomewide gene expression analysis using si*‐SDC3*‐treated 786‐O cells to investigate which genes were modulated by *SDC3*. A SurePrint G3 Human GE 60K v3 microarray (Agilent Technologies) was used for genomewide expression analysis. We focused on genes that were significantly downregulated by transfection of both si*‐SDC3*\_1 and si‐*SDC3*\_2 (log~2~ \[average‐si*‐SDC3*/mock\] \< −1.0). *SDC3* was the most significantly downregulated gene, indicating that the array data were worthy of evaluation. We identified 26 candidate genes (Table [4](#cas13722-tbl-0004){ref-type="table"}), from which a gene expression heat map was constructed (Figure [8](#cas13722-fig-0008){ref-type="fig"}A). In the heat map, we focused on a gene cluster including *SDC3* (*IL18RAP*,*SDC3*,*SH2D1A*,*GZMH*,*KIF21B*,*TMC8*,*GAB3*,*HLA‐DPB2*,*PLEK*, and *C1Qb*) (Figure [8](#cas13722-fig-0008){ref-type="fig"}B). Furthermore, patients with high gene signature expression (Figure [8](#cas13722-fig-0008){ref-type="fig"}B, red square) were significantly associated with a lower overall survival rate than those with low gene signature expression (Figure [8](#cas13722-fig-0008){ref-type="fig"}B, blue square) (*P* = 0.0064, Figure [8](#cas13722-fig-0008){ref-type="fig"}C). Furthermore, high expression of 7 genes (*SDC3*,*PLXDC1*,*IL18RAP*,*GZMH*,*ATP8B3*,*TBX15*, and *TMC8*) was significantly associated with poor prognosis of RCC patients by TCGA datasets (Figure [S3](#cas13722-sup-0003){ref-type="supplementary-material"}).

###### 

Candidate downstream genes of *SDC3* in renal cell carcinoma cells

  Gene symbol   Gene name                                                                   Log~2~ (si‐*SDC3*\_1/mock)   Log~2~ (si‐*SDC3*\_2/mock)   Average Log~2~ (si‐*SDC3*/mock)   GEO expression data fold change (tumor/normal)   Cytoband       TCGA data OS (*P*‐value)
  ------------- --------------------------------------------------------------------------- ---------------------------- ---------------------------- --------------------------------- ------------------------------------------------ -------------- -------------------------------------------------
  *SDC3*        Syndecan 3                                                                  −2.319                       −2.821                       −2.570                            2.432                                            hs\|1p35.2     0.000271
  *GAB3*        GRB2‐associated binding protein 3                                           −1.599                       −1.879                       −1.739                            2.467                                            hs\|Xq28       0.200000
  *PLXDC1*      Plexin domain containing 1                                                  −0.481                       −2.365                       −1.423                            3.144                                            hs\|17q12      0.001860
  *SH2D1A*      SH2 domain containing 1A                                                    −1.092                       −1.692                       −1.392                            2.214                                            hs\|Xq25       0.133000
  *SFMBT2*      Scm‐like with four mbt domains 2                                            −1.240                       −1.434                       −1.337                            2.189                                            hs\|10p14      0.009770[a](#cas13722-note-0007){ref-type="fn"}
  *NFATC2*      Nuclear factor of activated T cells, cytoplasmic, calcineurin‐dependent 2   −1.036                       −1.624                       −1.330                            2.259                                            hs\|20q13.2    0.002260[a](#cas13722-note-0007){ref-type="fn"}
  *KIF21B*      Kinesin family member 21B                                                   −1.385                       −1.231                       −1.308                            2.701                                            hs\|1q32.1     0.148000
  *NLGN1*       Neuroligin 1                                                                −0.971                       −1.518                       −1.244                            2.423                                            hs\|3q26.31    0.039100[a](#cas13722-note-0007){ref-type="fn"}
  *PREX2*       Phosphatidylinositol‐3,4,5‐trisphosphate‐dependent Rac exchange factor 2    −1.088                       −1.390                       −1.239                            2.213                                            hs\|8q13.2     0.069000
  *CALHM2*      Calcium homeostasis modulator 2                                             −1.858                       −0.617                       −1.237                            2.940                                            hs\|10q24.33   0.135000
  *IL18RAP*     Interleukin 18 receptor accessory protein                                   −0.431                       −1.976                       −1.203                            3.967                                            hs\|2q12.1     0.001070
  *PLEK*        Pleckstrin                                                                  −1.275                       −1.123                       −1.199                            3.395                                            hs\|2p13.3     0.121000
  *PECAM1*      Platelet/endothelial cell adhesion molecule 1                               −0.465                       −1.931                       −1.198                            2.831                                            hs\|17q23.3    0.036500[a](#cas13722-note-0007){ref-type="fn"}
  *ZNF660*      Zinc finger protein 660                                                     −0.452                       −1.913                       −1.183                            2.274                                            hs\|3p21.31    0.155000
  *ELTD1*       EGF, latrophilin, and seven transmembrane domain containing 1               −0.634                       −1.612                       −1.123                            2.297                                            hs\|1p31.1     No data
  *KCNJ8*       Potassium channel, inwardly rectifying subfamily J, member 8                −0.465                       −1.720                       −1.093                            2.002                                            hs\|12p12.1    0.495000
  *ITGA4*       Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA‐4 receptor)        −0.369                       −1.788                       −1.079                            2.336                                            hs\|2q31.3     0.573000
  *GZMH*        Granzyme H (cathepsin G‐like 2, protein h‐CCPX)                             −0.273                       −1.882                       −1.077                            5.323                                            hs\|14q12      0.012900
  *ATP8B3*      ATPase, aminophospholipid transporter, class I, type 8B, member 3           −0.470                       −1.647                       −1.059                            2.941                                            hs\|19p13.3    7.35E‐07
  *ZG16B*       Zymogen granule protein 16B                                                 −1.156                       −0.955                       −1.056                            2.080                                            hs\|16p13.3    0.596000
  *HLA‐DPB2*    Major histocompatibility complex, class II, DP beta 2 (pseudogene)          −0.988                       −1.111                       −1.050                            3.123                                            hs\|6p21.32    0.968000
  *TBX15*       T‐box 15                                                                    −0.442                       −1.631                       −1.036                            4.119                                            hs\|1p12       0.001930
  *C1QB*        Complement component 1, q subcomponent, B chain                             −1.363                       −0.661                       −1.012                            6.547                                            hs\|1p36.12    0.070700
  *TMC8*        Transmembrane channel‐like 8                                                −0.651                       −1.370                       −1.011                            2.786                                            hs\|17q25.3    0.001460
  *SLITRK5*     SLIT and NTRK‐like family, member 5                                         −1.372                       −0.636                       −1.004                            5.478                                            hs\|13q31.2    0.016200[a](#cas13722-note-0007){ref-type="fn"}
  *HECW2*       HECT, C2, and WW domain containing E3 ubiquitin protein ligase 2            −0.984                       −1.017                       −1.000                            2.663                                            hs\|2q32.3     0.000152[a](#cas13722-note-0007){ref-type="fn"}

Poor prognosis with low expression.

GEO, Gene Expression Omnibus; OS, overall survival; TCGA, The Cancer Genome Atlas.
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![Heat map showing gene expression and Kaplan‐Meier analysis in renal cell carcinoma cells. A, Heat map visualization of candidate genes downstream from *SDC3*. B, Heat map visualization of a gene signature including *SDC3* (black square). C, Kaplan‐Meier analysis of overall survival of patients with high gene signature expression (red square) and those with a low gene signature expression (blue square)](CAS-109-2919-g008){#cas13722-fig-0008}

3.9. Analysis of pre‐miR‐144 and the SDC family in RCC pathogenesis and clinical outcome from TCGA database {#cas13722-sec-0024}
-----------------------------------------------------------------------------------------------------------

Figure [9](#cas13722-fig-0009){ref-type="fig"}A shows that patients with high expression of *SDC3* had shorter disease‐free survival. Furthermore, high expression of *SDC3* was significantly associated with advanced tumor stage and high pathological grade (Figure [9](#cas13722-fig-0009){ref-type="fig"}B‐F).

![The Cancer Genome Atlas database analysis of *SDC3* in renal cell carcinoma. A, Patients with high *SDC3* expression had shorter disease‐free survival than those with low expression. B‐F, High *SDC3* expression was significantly associated with advanced tumor stage and pathological grade](CAS-109-2919-g009){#cas13722-fig-0009}

Conversely, low expression levels of *miR‐144‐5p* and *miR‐144‐3p* were significantly associated with shorter disease‐free survival and advanced tumor stage (Figure [S4](#cas13722-sup-0004){ref-type="supplementary-material"}).

The univariate and multivariate Cox proportional hazards model showed that high expression of *SDC3* was an independent predictive factor for survival (hazard ratio, 1.77; 95% confidence interval, 1.07‐2.97; *P* = 0.0249), as were well‐known clinical prognostic factors such as T stage, M stage, and hemoglobin level (Table [5](#cas13722-tbl-0005){ref-type="table"}).

###### 

Univariable and multivariable Cox hazard regression models for overall survival in renal cell carcinoma

  Variable             Group               Univariable   Multivariable                                  
  -------------------- ------------------- ------------- --------------- ---------- ------ ------------ ----------
  *SDC3* expression    High/low            1.73          1.28‐2.36       0.0003     1.77   1.07‐2.97    0.0249
  Age, years           ≥60/\<60            1.84          1.35‐2.54       0.0001     1.51   0.91‐2.57    0.1131
  Gender               Male/female         0.97          0.72‐1.34       0.8684     --     --           --
  T stage              3 + 4/1 + 2         3.05          2.26‐4.14       \<0.0001   2.94   1.05‐10.44   0.0381
  N stage              Positive/negative   3.07          1.49‐5.65       0.0038     0.66   0.19‐1.95    0.4708
  M stage              Positive/negative   4.27          3.11‐5.82       \<0.0001   5.11   2.57‐10.07   \<0.0001
  Stage                III + IV/I + II     3.72          2.72‐5.13       \<0.0001   0.55   0.14‐1.82    0.3423
  Histological grade   G3 + 4/G1 + 2       2.59          1.86‐3.68       \<0.0001   1.06   0.62‐1.86    0.8232
  Serum Ca level       High/normal         4.38          2.06‐8.18       0.0005     0.74   0.19‐2.33    0.6173
  Serum Hb level       Low/normal          2.13          1.52‐3.05       \<0.0001   1.67   1.00‐2.89    0.0488

--, not included in analysis. Ca, calcium; CI, confidence interval; Hb, hemoglobin; HR, hazard ratio.

John Wiley & Sons, Ltd

In further analyses, we investigated the relationships between other genes in the syndecan family (*SDC1*,*SDC2*, and *SDC4*) and RCC pathogenesis. Interestingly, no other *SDC* family gene had a significant relationship between its expression and patient prognosis, tumor stage, or pathological grade in RCC (Figure [S5](#cas13722-sup-0005){ref-type="supplementary-material"}).

3.10. Effect of cotransfection of *SDC3/miR‐144‐5p* in 786‐O cells {#cas13722-sec-0025}
------------------------------------------------------------------

In order to investigate whether the *SDC3*/*miR‐144‐5p* axis is essential for RCC pathogenesis, we applied rescue studies in 786‐O cells. Our present studies showed that cell proliferation, migration, and invasive abilities were recovered by cotransfection of *SDC3* expression vector and *miR‐455‐5p* mature miRNA compared to *miR‐144‐5p* transfection alone (Figure [10](#cas13722-fig-0010){ref-type="fig"}). These findings suggested that overexpression of *SDC3* contributed to aggressiveness of RCC cells.

![Effects of cotransfection of *SDC3*/*miR‐144‐5p* into 786‐O cells. A, Syndecan‐3 (SDC3) protein expression was evaluated by Western blot analysis of 786‐O cells. The rescue studies were evaluated 48 hours after reverse transfection with *miR‐144‐5p* and 24 hours after forward transfection with the *SDC3* vector. GAPDH was used as a loading control. B, Cell proliferation was determined using XTT assays 72 hours after reverse transfection with *miR‐144‐5p* and 48 hours after forward transfection with the *SDC3* vector. C, Cell migration activity was assessed by wound healing assays 48 hours after reverse transfection with *miR‐144‐5p* and 24 hours after forward transfection with the *SDC3* vector. D, Cell invasive activity was evaluated by invasion assays 48 hours after reverse transfection with *miR‐144‐5p* and 24 hours after forward transfection with *SDC3* vector. \**P* \< .005, \*\**P* \< .0001. VC, vector control](CAS-109-2919-g010){#cas13722-fig-0010}

A schema summarizing these results of the study is shown in Figure [S6](#cas13722-sup-0006){ref-type="supplementary-material"}.

4. DISCUSSION {#cas13722-sec-0026}
=============

The general understanding of miRNA biogenesis posits that only guide strands of miRNAs (derived from the miRNA duplex) are incorporated into the RISC and actually modulate target RNA transcripts.[25](#cas13722-bib-0025){ref-type="ref"} Passenger strands of miRNAs are also thought to undergo degradation, becoming nonfunctional.[26](#cas13722-bib-0026){ref-type="ref"} Contrary to this point of view, our miRNA signatures showed that some miRNA passenger strands were aberrantly expressed in several cancer tissues.[15](#cas13722-bib-0015){ref-type="ref"}, [17](#cas13722-bib-0017){ref-type="ref"} Our previous studies revealed that *miR‐145‐3p* (the passenger strand of the *miR‐145* duplex) was significantly reduced in clinical specimens of prostate cancer as well as head and neck squamous cell carcinoma. Moreover, ectopic expression of *miR‐145‐3p* blocked cancer cell aggressiveness, suggesting that the passenger strand of the *miR‐145* duplex acts as an antitumor miRNA, as does *miR‐145‐5p* (the guide strand).[15](#cas13722-bib-0015){ref-type="ref"}, [16](#cas13722-bib-0016){ref-type="ref"} Moreover, *miR‐145‐3p* was incorporated into the RISC and targeted several oncogenes (eg *MELK*,*NCAPG*,*BUB1*,*CDK1*, and *MYO1B*) in cancer cells.[15](#cas13722-bib-0015){ref-type="ref"}, [16](#cas13722-bib-0016){ref-type="ref"} Importantly, these *miR‐145‐3p* targets were deeply involved in cancer pathogenesis. For example, high expression of *MELK*,*NCAPG*,*BUB1*, and *CDK1* significantly predicted survival in patients with prostate cancer.[15](#cas13722-bib-0015){ref-type="ref"}

Some miRNAs are distributed in clusters on human chromosomes.[27](#cas13722-bib-0027){ref-type="ref"} Analyses of our miRNA signature of RCC based on RNA sequencing showed that *miR‐451a* was significantly downregulated in cancer tissues and it had antitumor functions.[13](#cas13722-bib-0013){ref-type="ref"} In the human genome, *miR‐451a*,*miR‐451b*,*miR‐4732*,*miR‐144‐5p*, and *miR‐144‐3p* form a miRNA cluster at 17q11.2. Among these miRNAs, low expression of *miR‐451a*,*miR‐144‐5p*, and *miR‐144‐3p* predicted poor prognosis of patients with RCC according to TCGA database analyses. Our data showed that both strands of *miR‐144‐5p* and *miR‐144‐3p* had antitumor functions in RCC cells. Many studies have reported that *miR‐144‐3p* acted as an antitumor miRNA in several types of cancers.[28](#cas13722-bib-0028){ref-type="ref"}, [29](#cas13722-bib-0029){ref-type="ref"} In contrast to recent analyses of *miR‐144‐3p*, few papers have examined the function of *miR‐144‐5p* in cancer cells. We previously showed that *miR‐144‐5p* had tumor‐suppressive functions through its targeting of *CCNE1* and *CCNE2* in bladder cancer.[18](#cas13722-bib-0018){ref-type="ref"} It is very interesting that members of this miRNA cluster at 17q11.2 have cancer‐suppressing effects. These results suggest that the anticancer effects of this miRNA cluster should be closely examined in many cancers.

In miRNA‐based cancer research, elucidation of target genes and RNA networks controlled by aberrantly expressed miRNAs is an important approach to better understanding the development and progression of tumors. In this study, we identified 65 putative targets of *miR‐144‐5p* regulation in RCC cells. Among these targets, high expression of 9 genes (*FAM64A*,*F2*,*TRIP13*,*ANKRD36*,*CENPF*,*NCAPG*,*CLEC2D*,*SDC3*, and *SEMA4B*) significantly predicted poor survival in patients with RCC (*P* \< .001), suggesting they might be good prognostic markers. Among them, coagulation factor 2 (*F2*), which was overexpressed in advanced RCC, is related to tumor progression in several types of cancers.[30](#cas13722-bib-0030){ref-type="ref"} Furthermore, centromere protein F (*CENPF*) was previously reported to be regulated by antitumor *miR‐205* and involved in prostate cancer pathogenesis.[31](#cas13722-bib-0031){ref-type="ref"} Non‐SMC condensin I complex, subunit G (*NCAPG*) was also directly regulated by *miR‐145‐3p* and associated with tumor development in prostate cancer.[15](#cas13722-bib-0015){ref-type="ref"}

In the present study, we focused on *SDC3* as a crucial oncogene directly regulated by *miR‐144‐5p* in RCC cells. The syndecan protein family consists of four transmembrane proteoglycans in mammals (*SDC1‐4*). In carcinogenesis, syndecans, integrins, and growth factor receptors interact and play important roles in cell signaling. They appear to be involved in both cancer initiation and progression.[32](#cas13722-bib-0032){ref-type="ref"} Although they are similar in molecular structure, it has been reported that their expression and biological roles in cancer cells are different. Relatively little is known about *SDC3*, whereas *SDC1*,*SDC2*, and *SDC4* have been shown to possess oncogenic functions in several types of cancers.[33](#cas13722-bib-0033){ref-type="ref"}, [34](#cas13722-bib-0034){ref-type="ref"}, [35](#cas13722-bib-0035){ref-type="ref"} *SDC3* is primarily expressed in nerve tissue and developed musculoskeletal tissues. Overexpression of the gene might be involved in perineural invasion and shorter survival in pancreatic cancer.[32](#cas13722-bib-0032){ref-type="ref"} *SDC3* and perlecan were particularly strongly expressed in tumor stromal vessels, indicating that these heparan sulfate proteoglycans play pivotal roles in tumor angiogenesis.[32](#cas13722-bib-0032){ref-type="ref"} Furthermore, the SDC3‐mediated signaling pathway might lead to prostate cancer cell migration, invasion, and metastasis.[32](#cas13722-bib-0032){ref-type="ref"} These findings indicate that *SDC3* expression could be associated with RCC progression.

Furthermore, we identified a gene signature of *SDC3* downstream and its expressions were significantly related to cancer aggressiveness. Among 26 downstream genes, several genes have already reported roles in RCC pathogenesis. *ITGA4* promoted cancer cell metastasis and the kinesin family was related to cell proliferation, invasion, and migration in RCC.[36](#cas13722-bib-0036){ref-type="ref"}, [37](#cas13722-bib-0037){ref-type="ref"} Interestingly, high expression of 7 genes (*SDC3*,*PLXDC1*,*IL18RAP*,*GZMH*,*ATP8B3*,*TBX15*, and *TMC8*) significantly predicted poor prognosis of RCC patients according to TCGA datasets. *PLXDC1* (also known as *TEM7*) was initially cloned as a high expression protein from vascular endothelium of human cancer.[38](#cas13722-bib-0038){ref-type="ref"} Several studies showed that its expression contributed to angiogenesis.[39](#cas13722-bib-0039){ref-type="ref"}, [40](#cas13722-bib-0040){ref-type="ref"} In gastric cancer, aberrant expression of *PLXDC1* enhanced cancer cell migration and invasive abilities.[41](#cas13722-bib-0041){ref-type="ref"} *TBX15* is a member of the T‐box family of transcription factors; dysregulated expression of some *TBX* members is involved in human disease and carcinogenesis.[42](#cas13722-bib-0042){ref-type="ref"} In thyroid cancer cells, expression of *TBX15* induced Bcl2 and Bcl‐XL (anti‐apoptotic proteins) expression and its overexpression played a role of anti‐apoptosis.[43](#cas13722-bib-0043){ref-type="ref"} These studies showed that *SDC3* and its regulatory network have potential to be therapeutic targets of RCC. Further analysis of *SDC3* could contribute to the development of novel therapeutic strategies for RCC.[44](#cas13722-bib-0044){ref-type="ref"}

In conclusion, we showed that the expression of both *miR‐144‐5p* and *miR‐144‐3p* was significantly downregulated in RCC tissues and that they functioned as tumor suppressors in RCC cells. We found that *SDC3* was directly regulated by *miR‐144‐5p* and that it is a significant gene in RCC pathogenesis. Overexpression of *SDC3* was involved in the pathogenesis of RCC and acted as an oncogene. The antitumor functionality of the passenger strand of miRNA is a new concept in cancer research. Searching for RNA networks controlled by passenger strands of miRNA is a new challenge in studies of RCC pathogenesis.
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